Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon May 03, 2022 6:02pm
163 Views
Post# 34652929

RE:RE:Bloom Burton ... FYI

RE:RE:Bloom Burton ... FYI
Doccole wrote:

Just watched it.  They anticipate a run up going into phase 2.  

do we think they will announce Nasdq uplist in the fall?

how high at best and worst can we expect our MC going into phase 2?



Oh my Doccole - that's a lot of questions ...

I will try to answer the NASDAQ question ... as he did give a little shout-out to the NASDAQ crew on his team.  That's a good thing.

The NASDAQ move is likely going to depend on a few things ...
first - the share price movement
2nd - the appetite from the US side
3rd - expected ATE advances and drug development

Therefore, I wouldn't bet on a 2022 co-list on the NASDAQ but I wouldn't rule it out completely.  I would be more inclined to bet on it happening in 2023 - but - you just never know if/when sentiment changes.

Regardless - the focus is on the science and getting to P2 and figuring out chronic.  There is no rush to get to the NASDAQ because we simply don't need to.

All in my opinion.
<< Previous
Bullboard Posts
Next >>